1. Natural killer cells occupy unique spatial neighborhoods in HER2 - and HER2 + human breast cancers.
- Author
-
Ehlers FAI, Blise KE, Betts CB, Sivagnanam S, Kooreman LFS, Hwang ES, Bos GMJ, Wieten L, and Coussens LM
- Subjects
- Tumor Microenvironment immunology, Disease Progression, Receptor, ErbB-2 analysis, Receptor, ErbB-2 metabolism, Lymphocyte Subsets immunology, Lymphocyte Subsets pathology, Cell Count, Spatial Analysis, Breast cytology, Breast immunology, Breast pathology, Cohort Studies, Humans, Female, Middle Aged, Aged, Proteomics methods, Immunotherapy methods, Killer Cells, Natural immunology, Killer Cells, Natural pathology, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating pathology, Breast Neoplasms immunology, Breast Neoplasms pathology, Breast Neoplasms therapy, Immunohistochemistry methods
- Abstract
Tumor-infiltrating lymphocytes are considered clinically beneficial in breast cancer, but the significance of natural killer (NK) cells is less well characterized. As increasing evidence has demonstrated that the spatial organization of immune cells in tumor microenvironments is a significant parameter for impacting disease progression as well as therapeutic responses, an improved understanding of tumor-infiltrating NK cells and their location within tumor contextures is needed to improve the design of effective NK cell-based therapies. In this study, we developed a multiplex immunohistochemistry (mIHC) antibody panel designed to quantitatively interrogate leukocyte lineages, focusing on NK cells and their phenotypes, in two independent breast cancer patient cohorts (n = 26 and n = 30). Owing to the clinical evidence supporting a significant role for NK cells in HER2
+ breast cancer in mediating responses to Trastuzumab, we further evaluated HER2- and HER2+ specimens separately. Consistent with literature, we found that CD3+ T cells were the dominant leukocyte subset across breast cancer specimens. In comparison, NK cells, identified by CD56 or NKp46 expression, were scarce in all specimens with low granzyme B expression indicating reduced cytotoxic functionality. Whereas NK cell density and phenotype did not appear to be influenced by HER2 status, spatial analysis revealed distinct NK cells phenotypes regarding their proximity to neoplastic tumor cells that associated with HER2 status. Spatial cellular neighborhood analysis revealed multiple unique neighborhood compositions surrounding NK cells, where NK cells from HER2- tumors were more frequently found proximal to neoplastic tumor cells, whereas NK cells from HER2+ tumors were instead more frequently found proximal to CD3+ T cells. This study establishes the utility of quantitative mIHC to evaluate NK cells at the single-cell spatial proteomics level and illustrates how spatial characteristics of NK cell neighborhoods vary within the context of HER2- and HER2+ breast cancers., Competing Interests: Declarations. Ethics approval: Cohort 1 samples were obtained from Duke University, Durham, USA. Informed consent was obtained from all human subjects included in this study. The study protocol was approved by the ethics committee IRB of Duke University (Pro00034242). Cohort 2 samples were obtained by Maastricht University Medical Center+, Maastricht, The Netherlands. The collection, storage, and use of tissue and patient data were performed in agreement with the “Code for Proper Secondary Use of Human Tissue in the Netherlands” and approved by the local ethics committee (METC 2019 − 1154). Consent for publication: Not applicable. Conflict of interest: C.B. Betts is an employee of, and holds equity in, Akoya Biosciences, Inc. L.M. Coussens has received reagent support from Cell Signaling Technologies, Syndax Pharmaceuticals, Inc., ZielBio, Inc., and Hibercell, Inc.; holds sponsored research agreements with Syndax Pharmaceuticals, Hibercell, Inc., Prospect Creek Foundation, Lustgarten Foundation for Pancreatic Cancer Research, Susan G. Komen Foundation and the National Foundation for Cancer Research; is on the Advisory Board for Carisma Therapeutics, Inc., CytomX Therapeutics, Inc., Kineta, Inc., Hibercell, Inc., Cell Signaling Technologies, Inc., Alkermes, Inc., Raska Pharma, Inc., NextCure, Guardian Bio, AstraZeneca Partner of Choice Network (OHSU Site Leader), Genenta Sciences, Pio Therapeutics Pty Ltd., and Lustgarten Foundation for Pancreatic Cancer Research Therapeutics Working Group, Inc., (© 2025. The Author(s).)- Published
- 2025
- Full Text
- View/download PDF